PT  - JOURNAL ARTICLE
AU  - Checkouri, Thomas
AU  - Gerschenfeld, Gaspard
AU  - Seners, Pierre
AU  - Yger, Marion
AU  - Hassen, Wagih Ben
AU  - Chausson, Nicolas
AU  - Olindo, Stéphane
AU  - Caroff, Jildaz
AU  - Marnat, Gaultier
AU  - Clarençon, Frédéric
AU  - Baron, Jean-Claude
AU  - Turc, Guillaume
AU  - Alamowitch, Sonia
AU - the TETRIS and PREDICT-RECANAL collaborators
TI  - Early recanalization among patients undergoing bridging therapy with tenecteplase or alteplase
AID  - 10.1101/2023.05.08.23289701
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.05.08.23289701
4099  - http://medrxiv.org/content/early/2023/05/10/2023.05.08.23289701.short
4100  - http://medrxiv.org/content/early/2023/05/10/2023.05.08.23289701.full
AB  - Background Intravenous thrombolysis (IVT) with alteplase or tenecteplase prior to mechanical thrombectomy (MT) is the recommended treatment for large-vessel occlusion acute ischemic stroke (LVOS). There are divergent data on whether these agents differ in terms of early recanalization (ER) rates before MT, and little data on their potential differences in terms of established ER predictors such as time elapsed between IVT and ER evaluation (IVT-to-EReval time), occlusion site and thrombus length.Methods We compared the likelihood of ER after IVT with tenecteplase or alteplase in anterior circulation LVOS patients from the PREDICT-RECANAL (alteplase) and TETRIS (tenecteplase) French multicenter registries. ER was defined as a modified thrombolysis in cerebral infarction score 2b-3 on first angiographic run or non–invasive vascular imaging (magnetic resonance or computed tomography angiography) in patients with early neurological improvement. Analyses were based on propensity score overlap weighting (PSOW, leading to an exact balance in baseline characteristics between the treatment groups) and confirmed with adjusted logistic regression (sensitivity analysis).Results A total of 1865 patients were included. ER occurred in 156/787 (19.8%) and 199/1078 (18.5%) patients treated with tenecteplase or alteplase, respectively (odds ratio, 1.09 [95%CI 0.83–1.44]; P=0.52). A differential effect of tenecteplase vs alteplase on the probability of ER according to thrombus length was observed (Pinteraction=0.003), with tenecteplase being associated with higher odds of ER in thrombi > 10 mm (odds ratio, 2.43 [95% CI 1.02-5.81]; P=0.04). There was no differential effect of tenecteplase vs alteplase on the likelihood of ER according to the IVT-to-EReval time (Pinteraction=0.40) or occlusion site (Pinteraction=0.80).Conclusion Both thrombolytics achieved ER in a fifth of LVOS patients, with potentially greater effect of tenecteplase in larger thrombi. There was no significant differential influence of IVT-to-EReval time or occlusion site on likelihood of ER.Competing Interest StatementFunding StatementThis research has received funding from the DMU Neurosciences of the APHP.Sorbonne Université and the "Investissements d'avenir" ANR-10-IAIHU-06.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Sorbonne University Research Ethics Committee (CER-2021-1053).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.AcTAlteplase compared to Tenecteplase trialASMDabsolute standardized mean differenceASPECTSAlberta Stroke Program Early CT ScoreCTAComputed tomography angiographyCSCcomprehensive stroke centerDSAdigital subtraction angiographyDWIdiffusion-weighted imagingERearly recanalizationEXTEND-IA TNKTenecteplase versus Alteplase before Endovascular Therapy for Ischemic Stroke trialFLAIRfluid-attenuated inversion recoveryICAinternal carotid arteryIVTintravenous thrombolysisIVT-to-EReval timetime between intravenous thrombolysis start and evaluation of early recanalizationLVOSlarge-vessel occlusion acute ischemic strokeMCAmiddle cerebral arteryMTmechanical thrombectomyNIHSSNational Institutes of Health Stroke ScalemTICImodified Thrombolysis in Cerebral infarctionPSCprimary stroke centerPSOWpropensity score overlap weightingSVSsusceptibility vessel signTETRISTenecteplase Treatment in Ischemic Stroke